NCT06246565View on ClinicalTrials.gov

A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

June 1, 2026

Conditions
Cough
Interventions
DRUG

HS-10383

HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.

DRUG

HS-10383 Placebo

HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY